metaEvidence - overview


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
metastatic (mCRPC) - 1st line (L1) castration-resistant prostate cancer (CRPC) metastatic (mCRPC) - 1st line (L1)
metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer
versus androgen deprivation therapy (ADT)
	abiraterone plus ADT vs. androgen deprivation therapy (ADT)	2	none	-	statistically conclusive 37 % decrease in deaths (OS) but the degree if certainty is unassessable	-
	apalutamide plus ADT vs. androgen deprivation therapy (ADT)	1	none	-	statistically conclusive 33 % decrease in deaths (OS) but the degree if certainty is unassessable	-
	docetaxel plus ADT vs. androgen deprivation therapy (ADT)	4	none	-	statistically conclusive 24 % decrease in deaths (OS) but the degree if certainty is unassessable	-
	enzalutamide plus ADT vs. androgen deprivation therapy (ADT)	2	none	-	suggested 34 % decrease in deaths (OS) but the degree if certainty is unassessable	-
versus docetaxel plus ADT
	abiraterone plus docetaxel plus ADT vs. docetaxel plus ADT	1	none	-	statistically conclusive 25 % decrease in deaths (OS) but the degree if certainty is unassessable	-
	darolutamide plus doxetaxel plus ADT vs. docetaxel plus ADT	1	none	-	statistically conclusive 32 % decrease in deaths (OS) but the degree if certainty is unassessable	-